Literature DB >> 19069311

Role of the ubiquitin-proteasome pathway in muscle atrophy in cachexia.

Didier Attaix1, Lydie Combaret, Daniel Béchet, Daniel Taillandier.   

Abstract

PURPOSE OF REVIEW: Increased ubiquitin-proteasome-dependent proteolysis is a major determinant of muscle wasting in numerous catabolic states, including cachexia. We discuss the implication of both mechanistic and clinical recent observations for preventing or attenuating the loss of muscle proteins. RECENT
FINDINGS: The ubiquitin-proteasome system (UPS) is the major proteolytic machinery systematically activated in cachexia and only proteasome inhibitors prevent increased proteolysis. The UPS has been recently demonstrated to degrade myosin heavy chain (i.e. a major contractile protein) and telethonin that plays a role in sarcomere integrity. The UPS is activated at the ubiquitination/deubiquitination and proteasome activity levels. The precise complex and interdependent signalling pathways and transcription factors (i.e. the FoxO family) responsible for the activation of the UPS are in part identified. Recent studies have also shown that FoxO3 activates not only the UPS, but also the transcription of autophagy-related genes.
SUMMARY: The exact role of the different muscle proteolytic systems and their respective substrates are still largely unknown. However, current studies in animal models of cachexia already identified new pharmacological approaches that could be useful to block or partially prevent muscle wasting in cachectic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19069311     DOI: 10.1097/spc.0b013e3283196ac2

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  19 in total

Review 1.  Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents.

Authors:  Subash C Gupta; Ji Hye Kim; Ramaswamy Kannappan; Simone Reuter; Patrick M Dougherty; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2011-05-12

2.  Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases.

Authors:  Viviana Moresi; Andrew H Williams; Eric Meadows; Jesse M Flynn; Matthew J Potthoff; John McAnally; John M Shelton; Johannes Backs; William H Klein; James A Richardson; Rhonda Bassel-Duby; Eric N Olson
Journal:  Cell       Date:  2010-10-01       Impact factor: 41.582

3.  C/EBPβ regulates dexamethasone-induced muscle cell atrophy and expression of atrogin-1 and MuRF1.

Authors:  Patricia Gonnella; Nima Alamdari; Steven Tizio; Zaira Aversa; Victoria Petkova; Per-Olof Hasselgren
Journal:  J Cell Biochem       Date:  2011-07       Impact factor: 4.429

Review 4.  Exercise training in chronic heart failure: improving skeletal muscle O2 transport and utilization.

Authors:  Daniel M Hirai; Timothy I Musch; David C Poole
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-08-28       Impact factor: 4.733

5.  Unacylated ghrelin restores insulin and autophagic signaling in skeletal muscle of diabetic mice.

Authors:  Bjorn T Tam; Xiao M Pei; Benjamin Y Yung; Shea P Yip; Lawrence W Chan; Cesar S Wong; Parco M Siu
Journal:  Pflugers Arch       Date:  2015-07-31       Impact factor: 3.657

6.  TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure.

Authors:  Kechun Tang; Peter D Wagner; Ellen C Breen
Journal:  J Cell Physiol       Date:  2010-02       Impact factor: 6.384

Review 7.  F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Authors:  Ammar Sukari; Irfana Muqbil; Ramzi M Mohammad; Philip A Philip; Asfar S Azmi
Journal:  Semin Cancer Biol       Date:  2016-01-21       Impact factor: 15.707

8.  Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure.

Authors:  Telma F Cunha; Aline V N Bacurau; Jose B N Moreira; Nathalie A Paixão; Juliane C Campos; Julio C B Ferreira; Marcelo L Leal; Carlos E Negrão; Anselmo S Moriscot; Ulrik Wisløff; Patricia C Brum
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance.

Authors:  Sílvia Busquets; Míriam Toledo; Marcel Orpí; David Massa; Maria Porta; Eva Capdevila; Núria Padilla; Valentina Frailis; Francisco J López-Soriano; H Q Han; Josep M Argilés
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-11-08       Impact factor: 12.910

10.  Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency.

Authors:  Cloé M Julienne; Jean-François Dumas; Caroline Goupille; Michelle Pinault; Cécile Berri; Anne Collin; Sophie Tesseraud; Charles Couet; Stephane Servais
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-31       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.